Certain cancer therapies provide better patient outcomes but an individual’s response to a given treatment often depends on the tumor’s genomic profile. The Guardant360® assay provides comprehensive genomic results from a simple blood draw in approximately seven days, helping physicians move beyond the limitations of tissue biopsies to match their patients with the most appropriate treatment. This is clearly illustrated in the real life example of an advanced stage breast cancer patient below. Recommend our liquid biopsy to your advanced stage cancer patient today – Guardant360®, the global leader in liquid biopsy.